Self-expandable metal stents (SEMS) have been mostly reserved for palliation of @entity1282 because of advanced @entity418 . Fully covered SEMS (FCSEMS) (ALIMAXX-E, Alveolus Inc, Charlotte, NC, USA) offer the choice of @entity532 occur or maximum therapeutic benefit is achieved. To our knowledge, their use has not been studied in @entity1 undergoing neoadjuvant therapy. The objectives of this study were the following: (i) to evaluate whether FCSEMS are useful in @entity1 receiving neoadjuvant therapy; and (ii) to assess ease of removability and tissue reaction to FCSEMS. FCSEMS (ALIMAXX-E, Alveolus Inc) were deployed in consecutive @entity1 with locally advanced @entity418 over a period of 14 months. All @entity1 were referred for neoadjuvant chemoradiation therapy after stenting. @entity1282 scores were assessed at 0 month, 1 month, 3 months, and 6 months. Barium swallow and endoscopy were performed for new symptoms and follow-up. Eleven @entity1 were treated with FCSEMS prior to neoadjuvant therapy (mean age 60.5 years, 55% white, 91% male). All but one stent were successfully placed. Strictures were located in the upper esophagus (n= 1), middle esophagus (n= 4), lower esophagus (n= 2), and gastroesophageal junction (n= 4). @entity1282 was significantly improved at 1 month (mean difference 3.12; 2.53-3.79 95% confidence interval [CI]), 3 months (mean difference 2.86, 2.19-3.53 95% CI), and 6 months (mean difference 2.56, 1.79-3.34 95% CI) compared with baseline. Three @entity1 (27%) experienced @entity662 or heartburn immediately following deployment. Only two @entity1 ultimately underwent surgical resection. The others were diagnosed with @entity3 prior to surgery, had disease progression in spite of neoadjuvant treatment, or died with the stent in place. Three @entity1 developed delayed complications: recurrent @entity1282 (n= 2) and @entity1727 (n= 1). Eight (73%) stents were subsequently removed, one because of complication ( @entity1727 ), one because of migration (recurrent @entity1282 ), one was incorrectly deployed, and five were felt to have satisfied their purpose. Stents remained in place for a mean duration of 100.36 days (range 0-105, median 84). Removal was characterized as very easy in all cases. Upon removal, @entity1066 at the proximal or distal edge of stents were noted in six @entity1 (75%), @entity1127 in four (50%), and granulation in six (75%). One stent (13%) became embedded but was easily lifted from tissue. There were no perforations. Neoadjuvant treatment may have contributed to improvement in @entity1282 scores. FCSEMS can be used to re-establish esophageal luminal patency in @entity1 undergoing neoadjuvant therapy for locally advanced @entity418 , resulting in significant improvement in @entity1282 over baseline. Tissue reaction to stents occurs but does not appear to impair removability.

A pilot study of fully covered self-expandable metal stents prior to neoadjuvant therapy for locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain'] @entity1127 :: ('MESH:D011127', 'Disease') :: ['polyps'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcerations'] @entity532 :: ('MESH:D003925', 'Disease') :: ['removability if complications'] @entity1727 :: ('MESH:D004937', 'Disease') :: ['tracheal-esophageal fistula'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['Dysphagia', 'dysphagia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity418 :: (MESH:D004938,Disease) :: ['esophageal cancer']
